Furosemide for patent ductus arteriosus during cyclooxygenase inhibitor therapy: A systematic review.

ABSTRACT:

Background

Although furosemide is used during cyclooxygenase (COX) inhibitor therapy for patent ductus arteriosus (PDA), there are concerns regarding increased ductal closure failure and acute renal failure (ARF). This systematic review explores the effects of furosemide during COX inhibitor therapy.

Methods

We searched MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi databases for randomized clinical trials that assessed furosemide during COX inhibitor therapy for PDA in preterm infants. The primary outcome measure was PDA closure failure. Mortality and other complications were also assessed. The risk of bias was assessed using the Cochrane risk-of-bias tool for randomized contro

SUBMITTER: Kitaoka H 

PROVIDER: S-EPMC11580366 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature